| Recruiting | A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adu Chronic Immune Thrombocytopenia | Phase 1 / Phase 2 | 2025-01-03 |
| Completed | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma Multiple Myeloma | Phase 1 | 2021-03-22 |
| Completed | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar C Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma | Phase 2 | 2015-10-01 |
| Completed | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metast Triple Negative Breast Cancer | Phase 2 | 2012-07-01 |
| Completed | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer Ovarian Cancer, Fallopian Cancer, Peritoneal Cancer | Phase 2 | 2010-04-01 |
| Completed | Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies Relapsed or Refractory Hematological Malignancies | Phase 1 | 2009-04-01 |
| Completed | Study of ENMD-2076 in Patients With Multiple Myeloma Multiple Myeloma | Phase 1 | 2008-12-01 |
| Completed | A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer Advanced Cancer | Phase 1 | 2008-04-01 |
| Completed | Phase 1 Study of MKC-1 in Patients With Advanced Cancer Advanced Cancer | Phase 1 | 2008-03-01 |
| Completed | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer Ovarian Cancer, Endometrial Cancer | Phase 2 | 2008-01-01 |
| Completed | Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2007-11-01 |
| Completed | Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Recurrent Glioblastoma Multiforme | Phase 2 | 2007-04-01 |
| Completed | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell C Metastatic Renal Cell Carcinoma | Phase 2 | 2007-02-01 |
| Completed | Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer Prostate Cancer | Phase 2 | 2006-11-01 |
| Completed | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Hematological Malignancies, Myelodysplasia, Agnogenic Myeloid Metaplasia | Phase 1 | 2006-11-01 |
| Completed | Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer Advanced Cancer, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | 2006-10-01 |
| Completed | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer Ovarian Cancer | Phase 2 | 2006-10-01 |
| Completed | A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tu Carcinoid Tumor | Phase 2 | 2006-05-01 |
| Completed | A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1 Breast Cancer | Phase 2 | 2006-01-01 |
| Completed | Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma Recurrent Glioblastoma Multiforme | Phase 2 | 2006-01-01 |
| Completed | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma Relapsed Multiple Myeloma, Plateau Phase Multiple Myeloma | Phase 2 | 2001-03-01 |
| Completed | Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Pati Carcinoma, Non-Small-Cell Lung | Phase 2 | — |